Loading
Life sciences · Journal article
Supportive Care in Cancer · October 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with immune-related adverse events (irAEs), including cardiotoxicity. This review provides a comprehensive overview of the incidence, mechanisms, diagnosis, and management of ICI-associated cardiotoxicity, highlighting emerging biomarkers, diagnostic algorithms, and risk stratification strategies. We conducted a narrative review of the literature, synthesizing findings from recent clinical studies, guidelines, and case reports concerning ICI-associated cardiovascular complications such as myocarditis, pericarditis, and arrhythmias. As a narrative rather than systematic review, studies were selected to illustrate current concepts and were not appraised against predefined eligibility criteria. ICIs are associated with a low overall incidence of cardiovascular toxicities; however, myocarditis remains the most severe and potentially life-threatening manifestation. Reported case-fatality estimates vary widely, and the highest figures derive largely from early case series and pharmacovigilance data. Emerging biomarkers, evolving risk stratification tools, and updated diagnostic and management frameworks may improve early recognition, guide timely intervention, and support multidisciplinary care for patients with suspected ICI-associated cardiotoxicity, although most supporting evidence remains retrospective. Early recognition and prompt management of ICI-associated cardiotoxicities are essential for improving patient outcomes. This review provides oncologists and cardiologists with updated diagnostic approaches, treatment frameworks, and practical considerations for monitoring at-risk patients, while acknowledging that current recommendations rest largely on low-certainty evidence.